154 related articles for article (PubMed ID: 12675332)
21. The intestinal mucosa as a reservoir of HIV-1 infection after successful HAART.
Belmonte L; Olmos M; Fanin A; Parodi C; Baré P; Concetti H; Pérez H; de Bracco MM; Cahn P
AIDS; 2007 Oct; 21(15):2106-8. PubMed ID: 17885303
[TBL] [Abstract][Full Text] [Related]
22. HIV viral load: the myth of the undetectable?
Pillay D
Rev Med Virol; 2002; 12(6):391-6. PubMed ID: 12410530
[TBL] [Abstract][Full Text] [Related]
23. Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome.
García-Gascó P; Maida I; Blanco F; Barreiro P; Martín-Carbonero L; Vispo E; González-Lahoz J; Soriano V
J Antimicrob Chemother; 2008 Mar; 61(3):699-704. PubMed ID: 18192682
[TBL] [Abstract][Full Text] [Related]
24. Update on HIV-1 viral load blips.
Nettles RE; Kieffer TL
Curr Opin HIV AIDS; 2006 Mar; 1(2):157-61. PubMed ID: 19372801
[TBL] [Abstract][Full Text] [Related]
25. Characterization of GBV-C infection in HIV-1 infected patients.
Canducci F; Uberti Foppa C; Boeri E; Racca S; Gallotta G; Grasso MA; Calori G; Lazzarin A; Clementi M
J Biol Regul Homeost Agents; 2003; 17(2):191-4. PubMed ID: 14518722
[TBL] [Abstract][Full Text] [Related]
26. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
[TBL] [Abstract][Full Text] [Related]
27. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
28. Nonadherence with pediatric human immunodeficiency virus therapy as medical neglect.
Roberts GM; Wheeler JG; Tucker NC; Hackler C; Young K; Maples HD; Darville T
Pediatrics; 2004 Sep; 114(3):e346-53. PubMed ID: 15342896
[TBL] [Abstract][Full Text] [Related]
29. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.
Benveniste O; Flahault A; Rollot F; Elbim C; Estaquier J; Pédron B; Duval X; Dereuddre-Bosquet N; Clayette P; Sterkers G; Simon A; Ameisen JC; Leport C
J Infect Dis; 2005 May; 191(10):1670-9. PubMed ID: 15838794
[TBL] [Abstract][Full Text] [Related]
30. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
[TBL] [Abstract][Full Text] [Related]
31. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
[TBL] [Abstract][Full Text] [Related]
32. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy.
Huang W; De Gruttola V; Fischl M; Hammer S; Richman D; Havlir D; Gulick R; Squires K; Mellors J
J Infect Dis; 2001 May; 183(10):1455-65. PubMed ID: 11319681
[TBL] [Abstract][Full Text] [Related]
33. Quantitative detection of HIV-1 RNA using NucliSens EasyQ HIV-1 assay.
Yao J; Liu Z; Ko LS; Pan G; Jiang Y
J Virol Methods; 2005 Oct; 129(1):40-6. PubMed ID: 15961170
[TBL] [Abstract][Full Text] [Related]
34. Analytical and clinical sensitivity of the Procleix Ultrio HIV-1/HCV/HBV assay in samples with a low viral load.
Katsoulidou A; Moschidis Z; Sypsa V; Chini M; Papatheodoridis GV; Tassopoulos NC; Mimidis K; Karafoulidou A; Hatzakis A
Vox Sang; 2007 Jan; 92(1):8-14. PubMed ID: 17181585
[TBL] [Abstract][Full Text] [Related]
35. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
36. [Genotypic resistance in HIV-1-infected patients with persistent low-level viremia].
Parra-Ruiz J; Alvarez M; Chueca N; Peña A; Pasquau J; López-Ruz MA; Maroto Mdel C; Hernández-Quero J; García F
Enferm Infecc Microbiol Clin; 2009 Feb; 27(2):75-80. PubMed ID: 19254638
[TBL] [Abstract][Full Text] [Related]
37. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
Paton NI; Aboulhab J
HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
[TBL] [Abstract][Full Text] [Related]
38. [Quantitation of human immunodeficiency virus type 1 RNA by ultrasensitive method in the analysis of samples with low viral load].
Nishida Y; Moriya K; Nagaizumi K; Inaba H; Amano K; Fukue H; Yamamoto Y; Arai M; Fukutake K
Rinsho Byori; 2000 Mar; 48(3):282-3. PubMed ID: 10804838
[TBL] [Abstract][Full Text] [Related]
39. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study.
Resino S; M Bellón J; Gurbindo D; Tomás Ramos J; Antonio León J; Jose Mellado M; Angeles Muñoz-Fernández M
Clin Infect Dis; 2003 Nov; 37(9):1216-25. PubMed ID: 14557967
[TBL] [Abstract][Full Text] [Related]
40. A novel approach to HIV therapy: highly active antiretroviral therapy and autologous hematopoietic cell transplantation.
Pippi F
Med Hypotheses; 2008; 70(2):291-3. PubMed ID: 17681707
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
